XSWX
SDZ
Market cap36bUSD
, Last price
CHF
Name
Sandoz Group AG
Chart & performance
P/E
—
P/S
—
EPS
2.12
Vol. 1Y
—
Shs. 5Y
0.27%
Rev. 5Y
2.88%
Div Yld LY
—
Div Yld TTM
—
Revenues
11.15b
+7.36%
Net income
919m
+91,812.09%
CFO
1.59b
+142.99%
Dividend
Apr 13, 20260.8 CHF/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharmaceuticals, often supplied to other entities. Sandoz is also a significant player in the biotechnology sector, providing protein-based products such as biosimilars and offering specialized manufacturing services within this field. Furthermore, it supplies anti-infective products, including active pharmaceutical ingredients (APIs) and intermediates, with a strong emphasis on antibiotics. Established in 1886, Sandoz maintains its headquarters in Rotkreuz, Switzerland.
Key people
Richard Saynor
Chief Executive Officer · since 2019
Karen Huebscher
Non-Executive Independent Vice Chairman of the Board · since 2023
Remco Steenbergen
Chief Financial Officer · since 2024
Christophe Delenta
President, Europe · since 2024
Keren Haruvi
President, North America · since 2021
Peter Stenico
President, International · since 2025
Claire D'Abreu-Hayling
Chief Scientific Officer · since 2022
Ingrid Sollerer
Chief Compliance Officer, Group General Counsel · since 2023
Glenn Gerecke
Chief Manufacturing and Supply Officer · since 2022
Rebecca Guntern
Chief Commercial Officer · since 2024
Tripti Jha
Chief People Officer · since 2023
Gilbert Ghostine
Non-Executive Independent Chairman of the Board · since 2023
Shamiram Feinglass
Non-Executive Independent Director · since 2023
Mathai Mammen
Non-Executive Independent Director · since 2024
Non-Executive Independent Director · since 2024
Non-Executive Independent Director · since 2024
Urs Riedener
Non-Executive Independent Director · since 2023
Aarti Shah
Non-Executive Independent Director · since 2023
Yannis Skoufalos
Non-Executive Independent Director · since 2023
Maria Varsellona
Non-Executive Independent Director · since 2023
Legal address
Centralbahnstrasse 4
Basel, BS 4051
CH
Basel, BS 4051
CH
Headquarters
Suurstoffi 14
Rotkreuz, ZG 6343
CH
Rotkreuz, ZG 6343
CH
Other language
Sandoz Group Ltd
Other language
Sandoz Group SA
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||